View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
September 29, 2016

Deals this week: Peakdale Molecular, Bristol-Myers Squibb, Ironwood Pharmaceuticals

Peakdale Molecular and Cresset BioMolecular Discovery have entered an agreement to further expand the former’s integrated drug discovery services.

Peakdale Molecular and Cresset BioMolecular Discovery have entered an agreement to further expand the former’s integrated drug discovery services.

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

The agreement enables Peakdale Molecular to broaden its drug discovery platform.

Bristol-Myers Squibb and Nektar Therapeutics have entered a clinical collaboration agreement to develop a potential treatment for five tumour types and other chronic indications.

The agreement allows Bristol-Myers Squibb’s Opdivo to be used as a PD-1 immune checkpoint inhibitor to evaluate the potentiality of Nektar’s investigational immune stimulatory medicine, NKTR-214.

The partnership enables the further development of NKTR-214.

Ironwood Pharmaceuticals has raised $150 million through the private placement of 8.375% notes, due 15 September 2026. The placement has been subscribed to by TSSP and other institutional investors.

The company plans to invest the funds to pay off the principal balance of Linaclotide Pharma’s 11% notes, due in 2024.

Siegfried Holding plans to raise proceeds of up to $149.62 million through the public offering of 2.125% hybrid bonds.

UBS Investment Bank and Zurcher Kantonalbank are acting as advisors for the offering.

"Siegfried Holding plans to raise proceeds of up to $149.62 million through the public offering of 2.125% hybrid bonds."

The company will utilise the funds to repay its existing bank loans and also for capital structure management.

Array BioPharma plans for an underwritten public offering of 18.4 million shares of its common stock. The company expects to raise $115 million through the offering.

J.P. Morgan Securities and Cowen and Company are acting as joint book running managers, while Stifel Financial Corp and Wells Fargo Securities are acting as lead managers, and Gross Cutler Seiler Dupont is acting as legal advisor for the offering, which is expected to be completed by 3 October.

The company intends to use the proceeds to advance its research and development (R&D) and clinical trial programmes for general corporate purposes and to increase the working capital.


Image: Bristol-Myers Squibb and Nektar Therapeutics have entered a clinical collaboration agreement. Photo: Courtesy of Rept0n1x.

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena